Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 72% Improvement Relative Risk Discharge 49% Recovery time 18% c19early.org/aa Wadhwa et al. CTRI/2021/03/031721 Spironolactone RCT LATE Is late treatment with antiandrogens beneficial for COVID-19? RCT 120 patients in India (February - April 2021) Lower progression (p=0.031) and higher discharge (p=0.048) Wadhwa et al., medRxiv, doi:10.1101/2022.07.01.22277163 Favors spironolactone Favors control
Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi
Wadhwa et al., medRxiv, doi:10.1101/2022.07.01.22277163 (Preprint), CTRI/2021/03/031721
Wadhwa et al., Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in.., medRxiv, doi:10.1101/2022.07.01.22277163 (Preprint), CTRI/2021/03/031721
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 120 hospitalized patients in India, 74 treated with spironolactone and dexamethasone, and 46 with dexamethasone, showing lower progression with treatment. Spironolactone 50mg once daily day 1, 25mg once daily until day 21.
risk of progression, 72.4% lower, RR 0.28, p = 0.03, treatment 4 of 74 (5.4%), control 9 of 46 (19.6%), NNT 7.1, progression to WHO >4.
risk of no hospital discharge, 49.5% lower, RR 0.51, p = 0.048, treatment 13 of 74 (17.6%), control 16 of 46 (34.8%), NNT 5.8.
recovery time, 18.2% lower, relative time 0.82, p = 0.06, treatment 74, control 46.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wadhwa et al., 2 Jul 2022, Randomized Controlled Trial, placebo-controlled, India, preprint, 18 authors, study period 1 February, 2021 - 30 April, 2021, trial CTRI/2021/03/031721.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.01.22277163; this version posted July 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . TITLE: Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi Bharti Wadhwa1*, Vikas Malhotra2, Sukhyanti Kerai1, Farah Husain1, Nalini Bala Pandey1, Kirti N Saxena1, Vinay Singh1, Tom M Quinn3,4*, Feng Li3, Erin Gaughan3,4, Manu ShankarHari3, Bethany Mills3, Jean Antonelli3, Annya Bruce3, Keith Finlayson3, Anne Moore3, Kevin Dhaliwal3,4*, Christopher Edwards5* *Corresponding authors Affiliations 1 Department of Anaesthesia, Maulana Azad Medical College, New Delhi, India 2 Department of ENT & Head and Neck Surgery, Maulana Azad Medical College & Associated Hospitals, New Delhi, India 3 Centre for Inflammation Research, The Queen’s Medical Research Institute, BioQuarter, The University of Edinburgh, Edinburgh, EH16 4TJ, UK 4 Royal Infirmary of Edinburgh, BioQuarter, Little France, Edinburgh, EH16 4SA, UK 5 Imperial College, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.07.01.22277163; this version posted July 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . ABSTRACT Background: In this phase 2 randomised placebo-controlled clinical trial, we hypothesised that blocking mineralocorticoid receptors with spironolactone in patients with COVID-19 is safe and may reduce illness severity. Methods: Hospitalised patients with confirmed COVID-19 were randomly allocated to low dose oral spironolactone (50mg day 1, then 25mg once daily for 21 days) or standard care in a 2:1 ratio. Both groups received dexamethasone 6mg for 10 days. Group allocation was blinded to the patient and research team. Primary outcomes were time to recovery, defined as the number of days until patients achieved WHO Ordinal Scale (OS) category ≤3, and the effect of spironolactone on aldosterone, D-dimer, angiotensin II and Von Willebrand Factor (VWF). Results: 120 patients were recruited in Delhi from 01 February to 30 April 2021. 74 were randomly assigned to spironolactone and dexamethasone (SpiroDex), and 46 to dexamethasone alone (Dex). There was no significant difference in the time to recovery between SpiroDex and Dex groups (SpiroDex median 4.5 days, Dex median 5.5 days, p = 0.055). SpiroDex patients had lower aldosterone levels on day 7 and lower D-dimer levels on days 4 and 7 (day 7 D-dimer mean SpiroDex 1.15μg/mL, Dex 3.15 μg/mL, p = 0.0004). There was no increase in adverse events in patients receiving SpiroDex. Post hoc analysis demonstrated reduced clinical deterioration (pre specified as escalating to WHO OS category >4) in the SpiroDex group vs Dex group (5.4% vs 19.6%). Conclusion: Low dose oral spironolactone in addition to dexamethasone was safe and reduced D-Dimer and aldosterone. Although time to recovery was not..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit